Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

SELVITA Aktie

>SELVITA Performance

1 Woche: 0%

1 Monat: -8,7%

3 Monate: -27,6%

6 Monate: -43,4%

1 Jahr: -59,5%

laufendes Jahr: -43,4%

>SELVITA Aktie

Name:

SELVITA S.A. SER.B ZY-,80

Land:

Polen

Sektor:

Gesundheit

ISIN/ Wkn:

PLSLVCR00029 / A2PTJJ

Symbol/ Ticker:

787 (Frankfurt)

Kürzel:

FRA:787, ETR:787, 787:GR

Index:

Webseite:

https://selvita.com/

Marktkapitalisierung:

119.43 Mio. EUR

Umsatz:

359.79 Mio. EUR

EBITDA:

30.95 Mio. EUR

Gewinn je Aktie:

-0.05 EUR

Schulden:

207.8 Mio. EUR

Liquide Mittel:

15.53 Mio. EUR

Umsatz-/ Gewinnwachstum:

18.2% / -

KGV/ KGV lG:

17.96 / -

KUV/ KBV/ PEG:

1.48 / 1.66 / -

Gewinnm./ Eigenkapitalr.:

-1.37% / -1.53%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

SELVITA

Letzte Datenerhebung:

04.07.25

>SELVITA Eigentümer

Aktien: 18.36 Mio. St.

f.h. Aktien: 13.93 Mio. St.

Insider Eigner: 21.18%

Instit. Eigner: 31.85%

Leerverk. Aktien: -

>SELVITA Peer Group

BIOCELTIX

CELON PHARMA

MABION

MEDAPP

MERCATOR MEDICAL

NEUCA

PURE BIOLOGICS

RYVU

SYNEKTIK

VOXEL

>SELVITA Chart & Kurs - Frankfurt

>SELVITA News

27.03.25 - 09:24	Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 (PR Newswire)
	KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024 and provided an update on its backlog for 2025. Key Highlights: In Q4 2024, Selvita generated EUR 22.5 million in commercial......

10.12.24 - 11:43	Selvita strengthens management structure in sales and drug development segment (PR Newswire)
	KRAKÓW, Poland, Dec. 10, 2024 /PRNewswire/ -- Selvita S.A. [WSE: SLV], a member of the mWIG40 index and one of Europe's leading preclinical CROs, announced strategic changes to its structure, strengthening its international sales team and drug development segment. Selvita is bolstering......

21.11.24 - 13:50	Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future (PR Newswire)
	KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q3 2024 and provided an update on its backlog for 2024 and 2025. Financial and Operational Highlights......

24.09.24 - 08:07	Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 (PR Newswire)
	KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024, earnings estimates for Q3 204 and backlog for 2024 and 2025. Financial and Operational......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram